Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE
- Conditions
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2015-08-05
- Lead Sponsor
- Egyptian Society of Liver Cancer
- Target Recruit Count
- 77
- Registration Number
- NCT01539018
- Locations
- 🇪🇬
Ain shams university, Cairo, Egypt
🇪🇬Cairo University Hospitals, Cairo, Egypt
🇪🇬National Liver Institute, Monofeiya, Egypt
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2015-02-27
- Lead Sponsor
- HMeany
- Target Recruit Count
- 17
- Registration Number
- NCT01518413
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital Boston/Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2012-01-16
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Thomas Kipps
- Target Recruit Count
- 4
- Registration Number
- NCT01510756
- Locations
- 🇺🇸
UCSD Medical Center, La Jolla, California, United States
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Cardarelli Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT01507064
- Locations
- 🇮🇹
UOSC Epatologia - Cardarelli Hospital, Napoli, Italy
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 6
- Registration Number
- NCT01498952
- Locations
- 🇺🇸
Research Site, Las Vegas, Nevada, United States
SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 496
- Registration Number
- NCT01482442
- Locations
- 🇫🇷
CHU Dijon Hôpital Bocage #22, Dijon, France
🇫🇷Hôpital Edouard Herriot #6, Lyon, France
🇫🇷Hôpital Saint Eloi #8, Montpellier, France
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
- Conditions
- Interventions
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2016-04-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01480817
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2021-09-17
- Target Recruit Count
- 132
- Registration Number
- NCT01444807
- Locations
- 🇮🇹
Enrico Cortesi, Roma, Italy
🇮🇹Istituto Tumori Milano, Milan, Mi, Italy
🇮🇹Cinzia Ortega, Alba, Italy
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2011-09-15
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT01434602
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sorafenib for Patients With Extensive Keloids
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Tirgan, Michael H., M.D.
- Target Recruit Count
- 60
- Registration Number
- NCT01425216
- Locations
- 🇺🇸
Michael H. Tirgan, MD, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.